MX2018011699A - Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1. - Google Patents

Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.

Info

Publication number
MX2018011699A
MX2018011699A MX2018011699A MX2018011699A MX2018011699A MX 2018011699 A MX2018011699 A MX 2018011699A MX 2018011699 A MX2018011699 A MX 2018011699A MX 2018011699 A MX2018011699 A MX 2018011699A MX 2018011699 A MX2018011699 A MX 2018011699A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
histamine
receptor antagonist
leukotriene receptor
inverse agonist
Prior art date
Application number
MX2018011699A
Other languages
English (en)
Inventor
Del Carmen García Armenta Patricia
Alonso Chavez Garcia José
Original Assignee
Federico Amezcua Amezcua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federico Amezcua Amezcua filed Critical Federico Amezcua Amezcua
Priority to MX2018011699A priority Critical patent/MX2018011699A/es
Publication of MX2018011699A publication Critical patent/MX2018011699A/es
Priority to US17/280,049 priority patent/US20220031687A1/en
Priority to PCT/MX2019/000100 priority patent/WO2020067866A1/es
Priority to EP19866151.4A priority patent/EP3858354A4/en
Priority to CA3113220A priority patent/CA3113220A1/en
Priority to CONC2021/0004992A priority patent/CO2021004992A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación sinérgica de un antagonista de los receptores de leucotrienos, como lo es el principio activo: montelukast y sus sales farmacéuticamente aceptables y un antagonista inverso de la histamina H1, como lo es el principio activo: ketotifeno y sus sales farmacéuticamente aceptables, los cuales se encuentran formulados con excipientes y/o vehículos y/o aditivos farmacéuticamente aceptables en una sola unidad de dosificación para ser administrado por vía oral, transdérmica o por dispositivos para inhalación oral, nasal, misma que está indicada para el tratamiento de la enfermedad atópica como: asma, rinitis alérgica y dermatitis atópica.
MX2018011699A 2018-09-26 2018-09-26 Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1. MX2018011699A (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2018011699A MX2018011699A (es) 2018-09-26 2018-09-26 Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
US17/280,049 US20220031687A1 (en) 2018-09-26 2019-09-20 Synergic pharmaceutical combination of a leukotriene-receptor antagonist and an inverse agonist of histamine hi
PCT/MX2019/000100 WO2020067866A1 (es) 2018-09-26 2019-09-20 Combinación farmacéutica sinérgica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1
EP19866151.4A EP3858354A4 (en) 2018-09-26 2019-09-20 SYNERGISTIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIEN RECEPTOR ANTAGONIST AND A HISTAMINE-H1 INVERSE AGONIST
CA3113220A CA3113220A1 (en) 2018-09-26 2019-09-20 Synergic pharmaceutical combination of a leukotriene-receptor antagonist and an inverse agonist of histamine h1
CONC2021/0004992A CO2021004992A2 (es) 2018-09-26 2021-04-19 Combinación farmacéutica sinérgica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018011699A MX2018011699A (es) 2018-09-26 2018-09-26 Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.

Publications (1)

Publication Number Publication Date
MX2018011699A true MX2018011699A (es) 2019-07-24

Family

ID=67998847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011699A MX2018011699A (es) 2018-09-26 2018-09-26 Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.

Country Status (6)

Country Link
US (1) US20220031687A1 (es)
EP (1) EP3858354A4 (es)
CA (1) CA3113220A1 (es)
CO (1) CO2021004992A2 (es)
MX (1) MX2018011699A (es)
WO (1) WO2020067866A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH531000A (de) 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8377994B2 (en) 2006-05-10 2013-02-19 Evonik Degussa GmeH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
TR201009398A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
WO2013148366A1 (en) 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Also Published As

Publication number Publication date
EP3858354A4 (en) 2022-03-16
EP3858354A1 (en) 2021-08-04
US20220031687A1 (en) 2022-02-03
WO2020067866A1 (es) 2020-04-02
CA3113220A1 (en) 2020-04-02
CO2021004992A2 (es) 2021-04-30

Similar Documents

Publication Publication Date Title
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
PE20191240A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
WO2015116856A3 (en) Farnesoid x receptor antagonists
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
WO2016168553A8 (en) Deuterated obeticholic acid
MX2019004096A (es) Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112019002513A2 (pt) uso e dosagem de agentes terapêuticos para endometriose
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
ZA202212128B (en) Combination of alcaftadine and a corticosteroid
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2019003339A (es) Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso.
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX2018011699A (es) Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
PH12017501736A1 (en) Indole derivatives
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
MX2019011485A (es) Composicion farmaceutica estabilizada para la administracion de un antagonista de leucotrieno en combinacion con un antagonista de la proteina receptora de la histamina h-1.
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
MX2018011142A (es) Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.